SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BigBear.ai Holdings, Inc. engages in data-driven decision dominance and advanced analytics that provide its customers with a competitive advantage in a world driven by data that is growing in terms of volume, variety, and velocity. The firm operationalizes artificial intelligence and machine learning at scale through its end-to-end data analytics platform. It deploys its observe, orient and dominate products to customers throughout the defense, intelligence, and commercial markets. The company was founded in 2020 and is headquartered in McLean, VA.

BigBear.ai Holdings Inc

BigBear.ai is trending with significant volume, fueled by speculation around potential government contracts and recent congressional disclosures of stock purchases. The community is closely watching key price levels, anticipating a continued upward trajectory and discussing potential catalysts like interest rate cuts. Some are drawing comparisons to Palantir, while others are eyeing potential breakouts.

Luckin Coffee, Inc. engages in providing food and beverage items, and operates coffee retail stores. It has a pioneered a technology-driven retail network to provide coffee and other products of high quality, high convenience and high affordability to customers. The company manages pick-up stores, relax stores, and delivery kitchens. It also offers tea, snacks, and light meals through its mobile application. The company was founded by Zhi Ya Qian, Fei Yang and Jin Yi Guo on June 16, 2017 and is headquartered in Xiamen, China.

Luckin Coffee Inc - ADR

LKNCY is trending as Starbucks' CEO's recent comments acknowledging Luckin's innovation and pricing strategies spark community discussion about the competitive landscape.  Many investors are also anticipating a potential relisting, while some express frustration with the stock's price action despite positive company developments. The community is closely watching expansion efforts and speculating on the implications of a potential Starbucks China deal.

Quoin Pharmaceuticals Ltd. engages in the development of therapeutic products for the treatment of rare and orphan diseases. Its product pipeline includes QRX003, QRX004, QRX007, and QRX008. The company was founded by Michael Myers and Denise Carter on March 5, 2018 and is headquartered in Ashburn, VA.

Quoin Pharmaceuticals Ltd - ADR

Quoin Pharmaceuticals ($QNRX) is trending due to community excitement around its low float and potential for a significant breakout, drawing comparisons to other recently successful low-float runners. Traders are closely watching for a break above key resistance levels, anticipating a possible short squeeze and rapid price appreciation. Discussions also involve the company's progress in clinical trials for Netherton Syndrome and the potential impact of these developments.

Turbo Energy SA provides energy solutions. It engages in the developing, manufacturing and distributing of photovoltaic products. The company was founded on September 18, 2013 and is headquartered in Valencia, Spain.

Turbo Energy S.A. - ADR

Turbo Energy (TURB) is trending due to news of a significant $53 million energy storage project in Spain, sparking a massive surge in price and volume. The community is actively discussing its low float and potential for continued upward momentum, drawing comparisons to other recent high-flying stocks. Some traders caution against chasing the rally and point to potential pullbacks.

MicroAlgo, Inc. operates as a holding company, which engages in the development and application of bespoke central processing algorithms. Its services include algorithm optimization, accelerating computing power without the need for hardware upgrades, lightweight data processing, and data intelligence. The company was founded May 14, 2018 and is headquartered in New York, NY.

MicroAlgo Inc

MicroAlgo ($MLGO) is trending as day traders discuss its potential for a short squeeze and compare it to previous high-flying stocks. Community members are pointing to the low float and past rallies, while also debating dilution risks and potential for a crypto treasury announcement. Some traders are expressing skepticism, labeling it a "scam" stock while others are anticipating a significant upward move.

MARA Holdings, Inc. is a digital asset technology company, which engages in mining cryptocurrencies with a focus on the Bitcoin ecosystem. It also deals with owning and operating bitcoin mining facilities or data centers, selling proprietary software or technology to third parties operating in the Bitcoin ecosystem, offering advisory and consulting services to support Bitcoin mining ventures in domestic and international jurisdictions, and generating electricity from renewable energy resources or methane gas capture to power Bitcoin mining projects. The company was founded on February 23, 2010 and is headquartered in Hallandale Beach, FL.

MARA Holdings Inc.

Marathon Digital Holdings Inc

Marathon Digital (MARA) is trending as traders discuss its potential correlation with Bitcoin's price movements and the upcoming Fed announcement, while some express concerns about potential share offerings. Community members are debating its valuation, short squeeze potential, and comparing it to other miners. Broader discussions include its position within the crypto mining sector and the impact of insider buying.

FGI Industries Ltd. engages in the supply of kitchen and bath products. Its products fall under the following categories: Sanitaryware, Bath Furniture, Shower Systems and Other. The Sanitaryware category offers bath products such as toilets, sinks, pedestals and toilet seats. The Bath Furniture category deals with wood and wood-substitute furniture for bathrooms, including vanities, mirrors, laundry and medicine cabinets, and other storage systems. The Shower Systems category includes a range of shower-related products such as shower walls, shower doors and shower basins. The Others category includes shower door and shower systems products, custom kitchen cabinetry, and other accessory items. The company was founded on May 26, 2021 and is headquartered in East Hanover, NJ.

FGI Industries Ltd

FGI is trending due to a reported 182% gain from specific call options, sparking community interest in its potential for high returns. The community is discussing whether FGI could be the next stock to experience a significant price surge, similar to other recent runners with low floats. Some traders are also debating the sustainability of FGI's momentum, questioning if it's driven by genuine catalysts or just a pump.

RCI Hospitality Holdings, Inc. engages in the provision of live adult entertainment and dining experiences. It operates through the following segments: Nightclubs and Bombshells. The Nightclubs segment includes adult entertainment. The Bombshells segment involves the operation of restaurants and bars. The company was founded by Robert L. Watters in 1983 and is headquartered in Houston, TX.

RCI Hospitality Holdings Inc

RCI Hospitality (RICK) is trending due to news of executives being indicted for an $8M tax fraud and bribery scheme, leading to significant price declines. The community is discussing potential outcomes, ranging from a possible epic squeeze if major shareholders hold firm, to concerns about management and the company's future. Some investors view the dip as a buying opportunity given the company's cash flow and potential asset value.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IONQ is trending due to excitement surrounding its acquisition of Oxford Ionics and the formation of IonQ Federal, sparking bullish sentiment and analyst upgrades. Community discussions revolve around the potential for significant gains, comparisons to other high-growth stocks, and debates about its valuation. The broader context includes growing interest in the quantum computing sector and upcoming presentations at the Quantum World Congress.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is trending as the community discusses Elon Musk's recent stock purchase and its potential impact, with some speculating about motivations ranging from securing his compensation package to squeezing shorts. Concerns about safety probes and competition in the EV market are also being weighed against potential catalysts like rate cuts and progress in AI and robotics. Traders are closely watching key price levels and the broader market's reaction to upcoming Fed decisions.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/tag/shuttle-pharmaceuticals">Shuttle Pharmaceuticals (NASDAQ: SHPH)</a> is doubling down on its mission to revolutionize cancer treatment with radiation therapy. In just a few short weeks, the company has achieved a series of notable milestones, from a promising Phase 2 trial update to the appointment of veteran biotech executive George Scorsis as Chairman of the Board.With its lead candidate Ropidoxuridine already making waves in glioblastoma trials, Shuttle Pharma is positioning itself at the forefront of oncology innovation. The moves come as Shuttle looks to emulate recent breakthroughs by industry leaders such as <a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/tag/lantheus-holdings/">Lantheus Holdings (NASDAQ: LNTH)</a> and <a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/tag/novartis/">Novartis (NYSE: NVS)</a>, both of which have brought radiopharmaceutical therapies to market using similar underlying science.<h3>George Scorsis Steps In as Chairman</h3>On Wednesday, <a target="_blank" rel="noopener noreferrer nofollow" href="https://shuttlepharma.com/shuttle-pharma-appoints-george-scorsis-chairman-of-the-board-of-directors/">Shuttle Pharma announced</a> George Scorsis as the new Chairman of its Board of Directors. Scorsis brings over 25 years of executive experience, particularly in highly regulated sectors including biotech and cannabis. His resume includes leadership roles at Liberty Health Sciences and Mettrum Health Corp., and he currently chairs both <a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/tag/awakn-life-sciences">Awakn Life Sciences (CSE: AWKN) (OTCQB: AWKNF)</a> and Entourage Health Corp.Commenting on <a target="_blank" rel="noopener noreferrer nofollow" href="https://shuttlepharma.com/shuttle-pharma-appoints-george-scorsis-chairman-of-the-board-of-directors/">his new role</a> at Shuttle, Scorsis stated:<blockquote>I am honored to take on the role of Chairman of Shuttle Pharma. The Company has a unique opportunity to leverage its radiation sensitizers to increase cancer cure rates, prolong patient survival and improve quality of life for patients suffering from glioblastoma. I look forward to providing guidance to support the Company as we look to improve the lives of millions of patients impacted by cancer.</blockquote>Scorsis also previously served as Chairman of <a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/tag/sol-global-investments">SOL Global Investments (CSE: SOL) (OTC: SOLCF)</a>, which further illustrates his deep involvement in pioneering healthcare ventures.His appointment reflects Shuttle’s strategic push to strengthen its leadership team as it enters a pivotal period of clinical and commercial development.<h3>Ropidoxuridine Phase 2 Trial Gains Momentum</h3>The heart of Shuttle Pharma’s pipeline is <a target="_blank" rel="noopener noreferrer nofollow" href="https://shuttlepharma.com/therapeutics/ropidoxuridine/">Ropidoxuridine</a> (IPdR), a novel radiation sensitizer currently in Phase 2 clinical trials for the treatment of glioblastoma. The aggressive brain cancer has limited treatment options and remains incurable. Shuttle’s approach aims to amplify the efficacy of radiation therapy while keeping side effects minimal.As of <a target="_blank" rel="noopener noreferrer nofollow" href="https://shuttlepharma.com/shuttle-pharma-fda-orphan-drug-nears-patient-enrollment-milestone-for-phase-2-clinical-trial/">May 8, 2025</a>, nearly 50% of the trial’s initial enrollment target had been met. Impressively, 84% of patients enrolled had completed all seven cycles of treatment. Trial sites—ranging from Georgetown University Medical Center to the Miami Cancer Institute—reported the drug was well tolerated, with toxicity scores not exceeding 2 on a 1-5 scale.Dr. Anatoly Dritschilo, who recently stepped down as Chairman and Chief Scientific Officer, <a target="_blank" rel="noopener noreferrer nofollow" href="https://shuttlepharma.com/shuttle-pharma-fda-orphan-drug-nears-patient-enrollment-milestone-for-phase-2-clinical-trial/">said</a>, “If approved, we believe that Ropidoxuridine has the potential to redefine the standard approach for how to care for patients with glioblastoma.”Patients are being randomized into two dose cohorts—1,200 mg/day and 960 mg/day—to determine the optimal regimen. Once identified, an additional 14 patients will be enrolled at the best dose to reach statistical significance. The trial aims to complete enrollment later this year, with data readouts expected in 2026.Chris Cooper, Shuttle’s interim CEO, <a target="_blank" rel="noopener noreferrer nofollow" href="https://shuttlepharma.com/shuttle-pharma-provides-corporate-update/">commented</a>:<blockquote>With nearly 50% of patient enrollment achieved in the initial randomized portion and 84% of enrolled patients completing all seven cycles, the trial is advancing steadily at esteemed cancer centers. Ropidoxuridine has been well-tolerated and we have begun analyzing pharmacokinetic and pharmacodynamic samples to optimize dosing and response. Our goal is to complete enrollment later this year, with follow-up and data readouts anticipated in 2026.</blockquote>The U.S. FDA has granted Orphan Drug Designation to Ropidoxuridine, giving Shuttle potential marketing exclusivity if approved. Given that an estimated 800,000 U.S. cancer patients undergo radiation therapy annually—and 400,000 of those for curative purposes—Shuttle’s target market is sizable and growing.Also Read: <a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/featured/5-minute-deep-dive-scorecard-is-shuttle-pharmaceuticals-nasdaq-shph-ready-for-a-massive-breakout/">5-Minute Deep Dive Scorecard: Is Shuttle Pharmaceuticals (NASDAQ: SHPH) Ready for a Massive Breakout?</a><h3>Innovation Extends Beyond the Clinic</h3>On May 15, 2025, Shuttle released a <a target="_blank" rel="noopener noreferrer nofollow" href="https://shuttlepharma.com/shuttle-pharma-provides-corporate-update/">corporate update</a> highlighting the company’s many recent developments. In addition to clinical progress, Shuttle has made strides in the diagnostics space. The company entered a sponsored research agreement with the University of California, San Francisco (UCSF) to develop a PSMA-targeted ligand for theranostic use in prostate cancer.Furthermore, Shuttle filed a <a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/stocks/biotech/shuttle-pharma-targets-prostate-cancer-with-psma-ligand-breakthrough/">provisional patent</a> titled “PSMA-Targeted PARP Inhibitor Conjugates for Precision Cancer Therapy.” The filing was developed with Dr. Alan Kozikowski, a medicinal chemist whose past work helped enable the development of Lantheus’ Pylarify and Novartis’ Pluvicto—two commercially successful radiopharmaceuticals.Shuttle’s recent underwritten <a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/stocks/biotech/shuttle-pharma-closes-5-75-million-offering/">public offering</a> helped solidify its financial footing, with $4.5 million in cash and equivalents reported as of March 31, 2025. That cash will fund both the ongoing clinical trial and preclinical research efforts.<h3>Strengthened Leadership Amid Key Transitions</h3>While Scorsis’ arrival marks a new chapter, Shuttle has also seen notable exits. Dr. Dritschilo resigned from the Board and his role as CSO, while Michael Vander Hoek, the company’s VP of Regulatory, announced his retirement effective June 10.New board members Oleh Nabyt and Joseph Tung join Scorsis in reinforcing Shuttle’s governance and bringing expanded business and legal acumen to the table.<h3>Looking Ahead</h3>Shuttle Pharmaceuticals appears to be building momentum across multiple fronts—clinical, intellectual property, diagnostics, and leadership. With a new Chairman in place, promising mid-trial results, and a strengthened pipeline backed by a scientific pedigree, the company is drawing comparisons to past success stories, such as Lantheus Holdings and Novartis.Investors will watch closely as the Ropidoxuridine trial progresses toward full enrollment and data publication in 2026. If Shuttle can successfully deliver on its ambitions, it could play a major role in transforming radiation therapy for cancer patients worldwide.Read Next: <a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/videos/shuttle-pharma-showcases-cancer-treatment-advancements-at-planet-microcap-vegas-2025/">This Biotech Stock Took The Center Stage at the Planet MicroCap Showcase: VEGAS 2025</a><a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/sign-up/">Our email list eats first! Get exclusive alerts on explosive stock picks like AST SpaceMobile (NASDAQ: ASTS), which shot up +533% after our profile. Get our email signals based on our proprietary 5-indicator system before any of our other platforms by clicking here.</a><a target="_blank" rel="noopener noreferrer nofollow" href="https://www.facebook.com/groups/WealthyVC">Join the Discussion in the WVC Facebook Investor Group</a>Do you have a stock tip or news story suggestion? Please email us at: <a target="_blank" rel="noopener noreferrer nofollow" href="mailto:invest@wealthyvc.com">invest@wealthyvc.com</a>.This report/release/profile is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation unless otherwise stated below.Wealthy VC and its employees are not Registered Investment Advisors, Broker-Dealers or a member of any association for other research providers in any jurisdiction whatsoever and we are not qualified to give financial advice. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Wealthy VC encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled through their website, news releases, and corporate filings, or is available from public sources and Wealthy VC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. Our website and newsletter are for entertainment purposes only. This website is NOT a source of unbiased information. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment.Release of Liability: Through the use of this email and/or website advertisement, by viewing or using it, you agree to hold Wealthy VC, its operators, owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. Wealthy VC-sponsored advertisements do not purport to provide an analysis of any company’s financial position, operations or prospects and this is not to be construed as a recommendation by Wealthy VC or an offer or solicitation to buy or sell any security. WealthyVC and our controlling entity 1000724287 Ontario Ltd have been compensated USD $7,500 per month for six months for investor relations by Shuttle Pharmaceuticals Holdings, Inc.None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provided herein. Instead, Wealthy VC strongly urges you to conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D and all reports published on SEDAR if the company featured is Canadian. Wealthy VC further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled.The Private Securities Litigation Reform Act of 1995 provides investors with a ‘safe harbor’ in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact and may be “forward-looking statements”. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this action may be identified through the use of words such as “projects”, “foresee”, “expects”, “will”, “anticipates”, “estimates”, “believes”, “understands”, or that by statements indicating certain actions “may”, “could”, or “might” occur. Understand there is no guarantee past performance will be indicative of future results. Past Performance is based on the security’s previous day’s closing price and the high of-day price during our promotional coverage.In preparing this publication, Wealthy VC has relied upon information supplied by various public sources and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this email and website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this email and website are believed to be reliable, however, Wealthy VC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of material facts from such advertisement. Wealthy VC is not responsible for any claims made by the companies advertised herein, nor is Wealthy VC responsible for any other promotional firm, its program or its structure.<a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/disclaimer/">View Full Disclaimer</a>

Shuttle Pharma Ramps Up Fight Against Glioblastoma With New Leadership, Promising Clinical Trial, and Bold Innovations

Others

George Scorsis takes helm as Chairman as Ropidoxuridine trial nears 50% enrollment and patent advances boost pipeline.

SOL Global Investments Corp. is an investment company, which engages in the small and mid-cap sectors. It operates through the following segments : Retail, Agriculture, Technology, Esports and Gaming, Cryptocurrency, and New Age Wellness. The firm focuses on cannabis industry in legal U.S. states. Its objective is to provide shareholders with a long term return through capital appreciation, dividends and interest from its investments and has also made investments in the beverage and e-gaming industries. The company was founded by Jonathan Gilbert on January 28, 2005 and is headquartered in Toronto, Canada.

SOL Global Investments Corp

Cut 25 bps

Cut 50+ bps

No change

Hike 25 bps

It’s Fed Decision Week. Polymarket gives a 90% chance of a 25 bps cut. What’s your call? 
 
*Powered by Polymarket

SOLCF
SOL Global Investments Corp

Feed

News

Sentiment

Fundamentals

Info

Latest SOLCF News

SOLCF SOL Global Investments Corp